Abbisko Cayman Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Abbisko Cayman's earnings are forecast to decline at 82% per annum while its annual revenue is expected to grow at 14.2% per year. EPS is expected to decline by 74.9% per annum. Return on equity is forecast to be -23.6% in 3 years.

Anahtar bilgiler

-82.0%

Kazanç büyüme oranı

-74.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	41.8%
Gelir büyüme oranı	14.2%
Gelecekteki özkaynak getirisi	-23.6%
Analist kapsamı	Low
Son güncelleme	02 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

Sep 30

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08

Kazanç ve Gelir Büyüme Tahminleri

SEHK:2256 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	273	-489	-323	N/A	3
12/31/2025	279	-443	-12	N/A	3
12/31/2024	515	-82	-176	-166	3
6/30/2024	497	-16	-64	-55	N/A
3/31/2024	258	-224	-260	-250	N/A
12/31/2023	19	-432	-457	-445	N/A
9/30/2023	19	-457	-463	-444	N/A
6/30/2023	19	-483	-468	-444	N/A
3/31/2023	10	-489	-417	-394	N/A
12/31/2022	N/A	-496	-367	-344	N/A
9/30/2022	11	-1,075	-289	-270	N/A
6/30/2022	23	-1,654	-212	-196	N/A
3/31/2022	23	-1,797	-219	-204	N/A
12/31/2021	23	-1,810	-182	-170	N/A
3/31/2021	7	-774	-130	-125	N/A
12/31/2020	N/A	-707	-127	-123	N/A
12/31/2019	4	-134	-86	-83	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2256 is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: 2256 is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: 2256 is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: 2256's revenue (14.2% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Yüksek Büyüme Geliri: 2256's revenue (14.2% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2256 is forecast to be unprofitable in 3 years.

Abbisko Cayman Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 37%

Consensus EPS estimates fall by 89%

Consensus revenue estimates increase by 2,172%

Consensus forecasts updated

Recent updates

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

First half 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.32 loss in 1H 2023)

Abbisko Cayman Limited to Report First Half, 2024 Results on Aug 12, 2024

Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib (ABSK011) in Combination with Atezolizumab for the 2024 Esmo-Gi Congress

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary

Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

Founder recently bought HK$358k worth of stock

Consensus revenue estimates decrease by 37%

Consensus EPS estimates fall by 89%

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Abbisko Cayman Limited, Annual General Meeting, Jun 18, 2024

Abbisko Cayman Limited to Report Fiscal Year 2023 Results on Mar 12, 2024

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib (ABSK021) in China

Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051

Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Founder recently bought HK$257k worth of stock

Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology

Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa

Founder recently bought HK$121k worth of stock

Consensus revenue estimates increase by 2,172%

Abbisko Cayman Limited to Report First Half, 2023 Results on Aug 15, 2023

Abbisko Cayman Limited Announces Resignation of Dr. XIA Gavin Guoyao as Non-Executive Director

Abbisko Therapeutics Co., Ltd. to Present the Updated Clinical Phase Ib Data of Pimicotinib (ABSK021)

US FDA Grants Breakthrough Therapy Designation for CSF-1R Inhibitor Pimicotinib(ABSK021) of Abbisko Therapeutics

Less than half of directors are independent

Abbisko Therapeutics Co., Ltd. Completed the Dosing of the First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Abbisko Cayman Limited Appoints Zhang Zidong as Chief Financial Officer

Less than half of directors are independent

Consensus forecasts updated

Key Executive recently bought HK$1.1m worth of stock

Less than half of directors are independent

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin